Eliminating cells gone astray

New England Journal of Medicine

Volumn 365, Issue 18, 2011, Pages 1735-1737

  Sadelain, Michel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THYMIDINE KINASE;

ADOPTIVE TRANSFER; BONE MARROW TRANSPLANTATION; CELL THERAPY; DEGENERATIVE DISEASE; DNA MODIFICATION; EDITORIAL; GENETIC DISORDER; GENOTOXICITY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL; HUMAN; MONOGENIC DISORDER; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SEVERE COMBINED IMMUNODEFICIENCY; T LYMPHOCYTE; TUMOR LYSIS SYNDROME;

EID: 80455173537     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1109971     Document Type: Editorial

References (10)

1. Miller JS, Warren EH, van den Brink MR, et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Biology Underlying Recurrence of Malignant Disease Following Allogeneic HSCT: graft-versus-tumor/leukemia reaction. Biol Blood Marrow Transplant 2010;16:565-86.
2. Kohn DB, Candotti F. Gene therapy fulfilling its promise. N Engl J Med 2009;360:518-21.
3. Kohn DB, Dotti G, Brentjens R, et al. CARs on track in the clinic. Mol Ther 2011;19:432-8.
4. Riviere I, Dunbar CE, Sadelain M. Hematopoietic stem cell engineering at a crossroads. Blood (in press).
5. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-51.
6. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33.
7. Lupo-Stanghellini MT, Provasi E, Bondanza A, Ciceri F, Bordignon C, Bonini C. Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. Hum Gene Ther 2010;21:241-50.
8. Di Stasi A, Tey S-K, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011;365: 1673-83.
9. Spencer DM, Wandless TJ, Schreiber SL, Crabtree GR. Controlling signal transduction with synthetic ligands. Science 1993; 262:1019-24. (Pubitemid 24035037)
10. Ellis J, Baum C, Benvenisty N, et al. Benefits of utilizing gene-modified iPSCs for clinical applications. Cell Stem Cell 2010;7:429-30.